503A vs 503B Compounding for GLP-1s: Which Pharmacy Type Serves You in 2026?

The Direct Answer

A 503A compounding pharmacy prepares medication for one named patient at a time, in response to a patient-specific prescription, under a state board of pharmacy license and USP <797> sterile-compounding standards. A 503B outsourcing facility registers with the FDA, is inspected against full Current Good Manufacturing Practice (CGMP), and may produce large batches without patient-specific prescriptions for hospitals and clinics to keep as office stock. For GLP-1s specifically, the FDA declared the tirzepatide shortage resolved on December 19, 2024, and the semaglutide shortage resolved on February 21, 2025; after the 2025 grace periods expired, routine bulk copies from 503B facilities ended, while patient-specific 503A compounding continues where a prescriber documents an individual clinical need.

That paragraph is the whole map. The rest of this article walks through it in order: where the two categories come from in the statute, who inspects whom, what actually changed when the shortages resolved, and how you can tell, as a patient, which type of pharmacy is filling your prescription and whether it is operating inside the rules.

Where 503A and 503B Come From: The Statute

The names are not marketing labels. They are literal section numbers of the Federal Food, Drug, and Cosmetic Act (FD&C Act), the core statute the FDA administers. Section 503A, codified at 21 U.S.C. 353a, describes traditional pharmacy compounding: a licensed pharmacist, in a licensed pharmacy, combining or altering ingredients to create a medication for an identified individual patient based on a valid prescription. Compounding done inside those conditions is exempt from three requirements that apply to manufactured drugs: FDA premarket approval, mandatory manufacturer labeling with adequate directions for use, and full CGMP.

Section 503B is younger, and it exists because of a disaster. In 2012, contaminated steroid injections shipped by the New England Compounding Center, a Massachusetts pharmacy acting far outside the traditional patient-specific model, caused a national fungal meningitis outbreak. According to the Centers for Disease Control and Prevention, that outbreak infected 753 people across 20 states and killed 64. Congress responded with the Drug Quality and Security Act of 2013, which created section 503B (21 U.S.C. 353b) and a new category of compounder: the outsourcing facility. An outsourcing facility may compound sterile drugs in bulk, without patient-specific prescriptions, and sell them to healthcare facilities as office stock. In exchange, it voluntarily registers with the FDA, submits to FDA inspection against full CGMP, reports adverse events directly to the agency, and pays an annual establishment fee.

The logic of the two-tier system is proportionate risk. A batch produced by an outsourcing facility might reach thousands of patients, so it is regulated like manufacturing. A preparation made by a 503A pharmacy reaches exactly one patient, so it is regulated like pharmacy practice, primarily through state boards. Our 2026 update on FDA compounding rules covers how the agency has applied this framework since the GLP-1 shortages ended.

Oversight, Side by Side

The practical differences between the categories come down to who watches, against what standard, and for whom the medication is made.

One point worth stating plainly, because marketing copy on both sides muddies it: neither category produces an FDA-approved drug. Approval attaches to a specific manufacturer's product and application, not to a molecule. Compounded preparations from 503A pharmacies and 503B facilities alike are lawful when the statutory conditions are met, but they are not themselves FDA-approved as drugs. Any provider that describes a compounded GLP-1 as FDA-approved is misstating the law, and our guide to compounded semaglutide safety in 2026 explains what oversight does and does not cover.

What Changed When the GLP-1 Shortages Resolved

Both sections of the statute contain a restriction that sat dormant during the shortage years: a compounder may not regularly produce what amounts to essentially a copy of a commercially available FDA-approved drug. While semaglutide and tirzepatide sat on the FDA's drug shortage list, the drugs were not considered commercially available in the statute's sense, so 503A pharmacies and 503B outsourcing facilities could compound versions at scale. That is the era when compounded GLP-1s became a mass-market phenomenon.

"...does not compound regularly or in inordinate amounts (as defined by the Secretary) any drug products that are essentially copies of a commercially available drug product."

The era ended on specific dates. Per the FDA's drug shortage database, the agency declared the tirzepatide shortage resolved on December 19, 2024, and the semaglutide shortage resolved on February 21, 2025. The FDA then set wind-down periods rather than demanding an overnight stop: 503A pharmacies were given until roughly 60 days after each resolution, and 503B outsourcing facilities until roughly 90 days, before the agency said it intended to begin enforcing the copies restrictions. By late spring 2025, routine batch production of copied semaglutide and tirzepatide at outsourcing facilities was over.

What survived is the older, narrower lane that existed before the shortages: section 503A's patient-specific pathway. A 503A pharmacy may still compound a GLP-1 preparation for an individual patient when the prescriber determines, and documents on the prescription, that the compounded version produces a significant difference for that patient compared with the commercially available product. That is a clinical judgment made one patient at a time, which is exactly what section 503A was written to permit. It is also why the compounded GLP-1 providers still operating lawfully in 2026 are built around 503A pharmacies and individualized prescriptions rather than warehouse-scale batches; our roundup of the best compounded GLP-1 providers applies that test to each one.

For patients who want the brand products instead, the manufacturers now operate direct channels, and access has broadened since the shortage years. Our LillyDirect Zepbound guide walks through the brand path, and our overview of the cheapest legal ways to get a GLP-1 online in 2026 maps the full landscape, brand and compounded alike.

How to Tell Which Type Serves You

As a patient, you can identify the model behind your medication with three questions. First, did a licensed provider evaluate you and write a prescription in your name before anything shipped? If yes, you are in the patient-specific world that section 503A governs. Second, will the provider name the pharmacy and its state license number? A legitimate operation will, because the license is publicly verifiable. Third, does the label on the vial identify the compounding pharmacy? A 503A preparation is labeled for you specifically; office-stock product from an outsourcing facility is labeled for facility use.

Here is how those questions resolve at Trimi. Trimi works exclusively with 503A compounding pharmacies: VialsRx, its primary partner, which holds Texas State Board of Pharmacy license #35264, and GreenwichRx. Every order begins with an online visit in which a licensed provider reviews your health history and decides whether treatment is appropriate; if it is, the prescription is written for you individually and sent to the pharmacy, which compounds it per that prescription. You can read the full sequence on our how it works page. Compounded semaglutide contains the active ingredient in Ozempic and Wegovy, and compounded tirzepatide contains the active ingredient in Mounjaro and Zepbound; each is prepared per individual prescription by a state-licensed 503A pharmacy and is not itself FDA-approved as a drug.

On what the underlying molecules can do, the reference points are the pivotal trials of the approved products. In the STEP 1 trial, published in the New England Journal of Medicine in 2021, adults taking semaglutide 2.4 mg lost an average of 14.9 percent of body weight over 68 weeks. In the SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022, tirzepatide at the highest studied dose produced an average 20.9 percent reduction in body weight over 72 weeks. Those trials studied the FDA-approved products, not compounded preparations, and individual results vary with any GLP-1 medication.

Frequently Asked Questions